CRISPR Therapeutics
CRSP
CRSP
83 hedge funds and large institutions have $293M invested in CRISPR Therapeutics in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
30% more funds holding
Funds holding: 64 → 83 (+19)
5.7% more ownership
Funds ownership: 24.77% → 30.47% (+5.7%)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Holders
83
Holding in Top 10
3
Calls
$3.23M
Puts
$1.56M
Top Buyers
| 1 | +$20.2M | |
| 2 | +$12.9M | |
| 3 | +$8.52M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.6M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.52M |
Top Sellers
| 1 | -$6.65M | |
| 2 | -$2.88M | |
| 3 | -$2.71M | |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$1.75M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.21M |